Tema Etfs LLC Raises Position in Arcellx, Inc. $ACLX

Key Points

• Tema Etfs LLC has significantly increased its stake in Arcellx, purchasing an additional 20,982 shares, raising its total holdings by 281.0% to 28,450 shares valued at approximately $1.87 million.
• Analysts have given Arcellx a consensus rating of "Buy" with an average target price of $114.31, following upgrades from firms like Scotiabank and Cantor Fitzgerald.
• Arcellx reported an EPS of ($0.94), outperforming analyst estimates, but its revenue of $7.55 million fell short of the projected $16.76 million.

Tema Etfs LLC lifted its stake in Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 281.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,450 shares of the company's stock after acquiring an additional 20,982 shares during the period. Tema Etfs LLC owned approximately 0.05% of Arcellx worth $1,866,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in ACLX. Invesco Ltd. boosted its holdings in shares of Arcellx by 15.7% in the fourth quarter. Invesco Ltd. now owns 26,550 shares of the company's stock worth $2,036,000 after acquiring an additional 3,610 shares during the period. Mariner LLC boosted its holdings in shares of Arcellx by 37.8% in the fourth quarter. Mariner LLC now owns 6,980 shares of the company's stock worth $535,000 after acquiring an additional 1,915 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Arcellx by 156.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 305,088 shares of the company's stock worth $23,400,000 after acquiring an additional 186,013 shares during the period. Hsbc Holdings PLC boosted its holdings in shares of Arcellx by 114.7% in the fourth quarter. Hsbc Holdings PLC now owns 6,383 shares of the company's stock worth $496,000 after acquiring an additional 3,410 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Arcellx by 15.9% in the fourth quarter. The Manufacturers Life Insurance Company now owns 98,314 shares of the company's stock worth $7,540,000 after acquiring an additional 13,475 shares during the period. 96.03% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Kavita Patel sold 1,500 shares of Arcellx stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $67.36, for a total transaction of $101,040.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 8.35% of the company's stock.

Arcellx Stock Down 1.2%

Shares of NASDAQ ACLX traded down $0.86 during mid-day trading on Friday, reaching $69.39. 518,763 shares of the company were exchanged, compared to its average volume of 604,355. Arcellx, Inc. has a 52 week low of $47.86 and a 52 week high of $107.37. The stock has a market capitalization of $3.85 billion, a PE ratio of -20.29 and a beta of 0.28. The company's 50 day moving average price is $69.28 and its 200 day moving average price is $65.76.

Arcellx (NASDAQ:ACLX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.03) by $0.09. Arcellx had a negative net margin of 329.93% and a negative return on equity of 43.04%. The company had revenue of $7.55 million during the quarter, compared to the consensus estimate of $16.76 million. On average, sell-side analysts predict that Arcellx, Inc. will post -1.58 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Scotiabank raised their price target on Arcellx from $93.00 to $133.00 and gave the stock a "sector outperform" rating in a report on Thursday, July 31st. Cantor Fitzgerald raised shares of Arcellx to a "strong-buy" rating in a report on Monday, August 4th. Citigroup began coverage on shares of Arcellx in a report on Tuesday, June 17th. They issued a "buy" rating and a $110.00 price target for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $115.00 price target on shares of Arcellx in a report on Monday, June 16th. Two analysts have rated the stock with a Strong Buy rating and thirteen have given a Buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $114.31.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).